Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer

Trial Profile

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2018

At a glance

  • Drugs Durvalumab (Primary) ; Olaparib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms DORA
  • Most Recent Events

    • 08 Nov 2018 Planned End Date changed from 1 Apr 2020 to 1 Dec 2020.
    • 08 Nov 2018 Planned primary completion date changed from 1 Oct 2019 to 1 Apr 2020.
    • 08 Nov 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top